Every three seconds, someone in the world develops dementia. There are over 55 million people worldwide currently living with dementia, and that number is projected to reach 139 million by 2050. In the United States alone, an estimated 7.4 million Americans aged 65 and older are living with Alzheimer’s in 2026 and health and long-term care costs for people living with the disease are projected to reach $409 billion this year.
The most devastating aspect of Alzheimer’s disease is not just its progression, but how late it is usually caught. By the time the first memory lapses appear, the disease has often been silently advancing for years, sometimes decades. For researchers, finding a way to detect Alzheimer’s risk early (before symptoms take hold) has been the defining challenge of modern neuroscience.
On April 22, 2026, a landmark study brought that goal significantly closer. And the answer, it turns out, may already be hiding in a common blood test that millions of people take every year.
What Scientists Discovered
A new study led by researchers at NYU Langone Health has found that a routine immune marker in the blood (one already measured in standard lab work) may predict a person’s risk of developing Alzheimer’s disease and related dementias years before any cognitive symptoms appear.
Scientists found that higher neutrophil levels, which are part of the body’s first immune response, were linked to a greater chance of developing dementia. The discovery suggests this common lab value could help flag at-risk individuals before symptoms appear. It also raises the possibility that immune cells themselves may be fueling the disease.
The study, published in the peer-reviewed journal Alzheimer’s & Dementia, is notable not just for what it found, but for the sheer scale on which it was conducted.
The researchers analyzed NLR data from nearly 400,000 patients from two health care systems, approximately 285,000 patients from four NYU Langone hospitals and nearly 85,000 from the Veterans Health Administration, covering medical records spanning from 2011 to 2023.
“Our study is the first large-scale investigation showing that neutrophil metrics are associated with increased risk of dementia in humans,” said study first author Dr. Tianshe (Mark) He, a data scientist in the Department of Psychiatry at NYU Grossman School of Medicine.
What Is the NLR And Why Does It Matter?
To understand the significance of this finding, it helps to know what the neutrophil-to-lymphocyte ratio (NLR) actually is and why it is already sitting in millions of medical records unread.
Neutrophils, a type of white blood cell circulating in the bloodstream, act as some of the body’s first responders to infection and inflammation. When the immune system is activated, their numbers can rise quickly, altering the balance between neutrophils and other immune cells. Doctors can measure this balance using a standard lab value called the neutrophil-to-lymphocyte ratio.
The critical point for patients and clinicians alike: the NLR is easily obtained from a complete blood cell count, which is used by clinicians to diagnose infection and other immune conditions. This is not a new, expensive, or specialized test. It is one of the most common lab values ordered in routine medical care, which means the data already exists for countless patients. The challenge has been that no one knew to look at it as a window into future brain health.
That may now be changing.
Who Is Most at Risk? What the Data Shows
The study’s findings were not uniform across all populations. This demographic detail carries significant clinical weight.
The risk associated with high NLR was notably higher for women and Hispanic patients, providing critical data for personalized health interventions.
This matters for several reasons. Almost two-thirds of Americans with Alzheimer’s are women, and older Hispanic Americans are about one and a half times as likely to have Alzheimer’s or other dementias as older White Americans. The new NLR finding aligns with these already-documented disparities.
For clinicians, this suggests that NLR screening could be especially valuable as part of a targeted early-detection strategy for higher-risk demographic groups, allowing for earlier intervention and monitoring before cognitive decline becomes visible.
Could Neutrophils Be More Than a Warning Sign?
Perhaps the most provocative dimension of this study is what it implies beyond early detection. Researchers are now asking a deeper question: are neutrophils simply reflecting disease risk from the sidelines or are they actively driving it?
The results support growing evidence that neutrophils may play a more active role in the disease process itself. In Alzheimer’s and other dementias, this damage may occur in blood vessels and brain tissue. Signs of neutrophil-driven inflammation have been observed in the brains of Alzheimer’s patients, and animal studies suggest these cells can accelerate disease progression.
If neutrophils are not passive bystanders but active contributors to neurodegeneration, the implications go far beyond diagnosis. They could become a direct target for therapy, meaning treatments designed to modulate inflammation and neutrophil activity could potentially slow or even prevent the progression of Alzheimer’s.
“These and future studies will show whether neutrophils are just a marker of Alzheimer’s disease or are actively causing dementia progression — in which case, they could make a compelling therapeutic target,” said Dr. Ramos-Cejudo.
Important Caveats: What This Study Does Not Mean
Strong findings deserve honest context and the researchers themselves are clear about the limits of what this study proves.
Researchers caution that a direct cause-and-effect relationship has not yet been confirmed. One challenge is that neutrophils have a very short lifespan and must be studied using fresh blood samples, unlike other cell types that can be stored for later analysis.
Equally important: a high NLR is a risk signal, not a diagnosis. NLR alone cannot predict dementia. It should be used together with other risk factors, such as age, genetics, and lifestyle.
In other words, patients who learn they have an elevated NLR should not interpret this as a certainty of developing Alzheimer’s. What it may offer is a reason to engage in closer monitoring, lifestyle modifications, and (as research matures) participation in prevention-focused interventions at a stage when intervention is most likely to still make a difference.
Where This Fits in the Broader Picture of Alzheimer’s Detection
This study does not stand alone. It arrives at a moment when the field of blood-based Alzheimer’s biomarkers is advancing rapidly across multiple fronts.
The FDA has already approved the first commercial blood test for Alzheimer’s detection: the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, which measures phosphorylated tau protein and beta-amyloid in adults over 55 with symptoms, with an accuracy rate of 91.7% in positive cases. A parallel study from UC San Diego found that the protein p-tau217 can predict dementia risk up to 25 years before symptoms emerge.
The NLR finding adds a different and complementary dimension to this landscape. Unlike the specialized biomarker tests, it requires no new testing infrastructure. The data is already being collected. Its potential lies in its accessibility: a widely available, low-cost signal that could help clinicians identify at-risk individuals earlier, at no additional burden to the healthcare system.
A low-cost blood signal will not solve Alzheimer’s, but it may sharpen the search for risk while people still feel well.
What Comes Next
The researchers at NYU Langone Health are not stopping here. Dr. Ramos-Cejudo’s team at the VIDA lab is now combining measurements of neutrophil activity with multiple brain imaging techniques, including PET scans and diffusion MRI, alongside cognitive testing in patients. The goal is to determine, with greater precision, whether neutrophils are reflecting Alzheimer’s risk or actively creating it.
There is currently no cure for dementia, but a lot can be done to support both people living with the illness and those who care for them. Early detection is one of the most powerful tools available, because it opens a window for intervention, lifestyle change, clinical trial participation, and preparation that a late diagnosis simply cannot provide.
Conclusion
The idea that a standard blood test (one already routinely ordered during annual check-ups) could one day serve as an early warning for Alzheimer’s disease represents a meaningful shift in how medicine might approach one of the world’s most feared conditions.
This study does not offer a silver bullet. But it does offer something arguably more important: a new way of looking at data that already exists, through a lens that might reveal the disease long before it is noticeable.
For the 55 million people living with dementia worldwide (and the hundreds of millions more who will develop it in the coming decades) the era of catching Alzheimer’s before it speaks may be closer than we think. And the clue may already be in your next routine blood draw.
If you or someone you know is concerned about memory or cognitive health, speak with a qualified healthcare provider. For more information on dementia research and support, visit the Alzheimer’s Association or Alzheimer’s Disease International.
